Bone loss after liver transplantation

We studied 35 adult patients (mean age = 43 yr) referred for orthotopic liver transplantation. Spinal bone mineral density was measured by quantitative computed tomography scanning before transplantation (n = 35) and at 3 mo (n = 21) and 12 mo (n = 11) after orthotopic liver transplantation. The readings were corrected to age 50 yr, using the regression equations derived from normal control subjects. Quantitative bone histological studies were performed in 17 patients before orthotopic liver transplantation and 3 mo after orthotopic liver transplantation. Before orthotopic liver transplantation, the corrected spinal bone mineral density in men was 108 ± 20 mg/cm3, less than in male control subjects (129 ± 22 mg/cm3, p < 0.005). In women patients the value was 117 ± 27 mg/cm3, and in female control subjects 126 ± 19 mg/cm3 (NS). However, women patients with primary biliary cirrhosis had lower spinal bone mineral density (106.5 ± 14.8) than female control subjects (p < 0.005). Histologically, the resorbing surface was near the normal mean, whereas the osteoblast surface, tetracycline surface and bone formation rate was lower in men (p < 0.05) but not women. Spinal bone mineral density decreased by 24% in the first 3 mo after orthotopic liver transplantation with no further decrease at 12 mo. Five patients had vertebral fractures within 6 mo of orthotopic liver transplantation. One patient fractured a wrist and three had osteonecrosis of the hip or knee. Bone histological studies 3 mo after orthotopic liver transplantation showed no change in resorbing surface but an increase in osteoblast surface from 2.1% ± 3.0% to 6.0% ± 7.0% (p < 0.05), increased bone formation in men (21 ± 31 to 80 ± 96 μm2/mm2 p < 0.05) and serum osteocalcin increased from 2.3 ± 0.3 pg/ml before transplantation to 5.9 ± 1.8 pg/ml (p <0.05). Bone loss was related to the number of hospital days after orthotopic liver transplantation (r = 0.79, p < 0.001) but not to any other factor, including prednisone and cyclosporin dose.

[1]  F. Melsen,et al.  Aseptic necrosis of bone following renal transplantation. Clinical and biochemical aspects and bone morphometry. , 2009, Acta medica Scandinavica.

[2]  E. Dickson,et al.  Bone disease in liver transplant recipients: incidence, timing, and risk factors. , 1991, Transplantation proceedings.

[3]  J. Galloway,et al.  Prevalence and prediction of osteopenia in chronic liver disease , 1990, Hepatology.

[4]  H. Genant,et al.  Effect of intermittent cyclical etidronate therapy on bone mass and fracture rate in women with postmenopausal osteoporosis. , 1990, The New England journal of medicine.

[5]  L. Raisz,et al.  Glucocorticoid-induced osteoporosis: pathogenesis and management. , 1990, Annals of internal medicine.

[6]  S. Posen,et al.  Osteoporosis and skeletal fractures in chronic liver disease. , 1990, Gut.

[7]  J. Reginster,et al.  PREVENTION OF POSTMENOPAUSAL BONE LOSS BY TILUDRONATE , 1989, The Lancet.

[8]  J. Eisman,et al.  POTENTIAL PROTECTION BY CYCLOSPORIN AGAINST GLUCOCORTICOID EFFECTS ON BONE , 1989, The Lancet.

[9]  A. Sheil,et al.  Human liver allograft rejection: severity, prognosis, and response to treatment. , 1989, Transplantation proceedings.

[10]  D. Chappard,et al.  Bone changes in alcoholic cirrhosis of the liver. A histomorphometric study. , 1989, Pathology, research and practice.

[11]  S. Epstein,et al.  The effect of cyclosporin A administration and its withdrawal on bone mineral metabolism in the rat. , 1989, Endocrinology.

[12]  G. Lausten,et al.  Necrosis of the femoral head after renal transplantation. , 1988, Acta orthopaedica Scandinavica.

[13]  R. Evans,et al.  Bone mass is low in relatives of osteoporotic patients. , 1988, Annals of internal medicine.

[14]  S. Epstein,et al.  Cyclosporin-A in vivo produces severe osteopenia in the rat: effect of dose and duration of administration. , 1988, Endocrinology.

[15]  J. Clèdes,et al.  BONE HISTOLOGY IN RENAL TRANSPLANT PATIENTS RECEIVING CYCLOSPORIN , 1988, The Lancet.

[16]  S. Wimalawansa,et al.  CALCITONIN FOR PREVENTION OF POSTMENOPAUSAL BONE LOSS , 1988, The Lancet.

[17]  S. P. Nielsen,et al.  Reversal of postmenopausal vertebral bone loss by oestrogen and progestogen: a double blind placebo controlled study , 1988, British medical journal.

[18]  M. Bassendine,et al.  Metabolic bone disease in primary biliary cirrhosis at presentation. , 1988, Gastroenterology.

[19]  J. Reginster,et al.  1-YEAR CONTROLLED RANDOMISED TRIAL OF PREVENTION OF EARLY POSTMENOPAUSAL BONE LOSS BY INTRANASAL CALCITONIN , 1987, The Lancet.

[20]  J. Compston.  Hepatic osteodystrophy: vitamin D metabolism in patients with liver disease. , 1986, Gut.

[21]  J. Haddad,et al.  Free 25-hydroxyvitamin D levels are normal in subjects with liver disease and reduced total 25-hydroxyvitamin D levels. , 1986, The Journal of clinical investigation.

[22]  H. Genant,et al.  Bone mineral content in early-postmenopausal and postmenopausal osteoporotic women: comparison of measurement methods. , 1986, Radiology.

[23]  K. Mann,et al.  Bone loss and reduced osteoblast function in primary biliary cirrhosis. , 1985, Annals of internal medicine.

[24]  M. Kaplan,et al.  Osteoporosis in primary biliary cirrhosis: effects of 25-hydroxyvitamin D3 treatment. , 1982, Gastroenterology.

[25]  R. Recker,et al.  Bone disease in primary biliary cirrhosis: histologic features and response to 25-hydroxyvitamin D. , 1982, Gastroenterology.

[26]  A. F. Stewart,et al.  Calcium homeostasis in immobilization: an example of resorptive hypercalciuria. , 1982, The New England journal of medicine.

[27]  I. Rosenberg,et al.  Bone disease in primary biliary cirrhosis: reversal of osteomalacia with oral 25-hydroxyvitamin D. , 1980, Gastroenterology.

[28]  R. P. Thompson,et al.  Treatment of osteomalacia associated with primary biliary cirrhosis with parenteral vitamin D2 or oral 25-hydroxyvitamin D3. , 1979, Gut.

[29]  T. Hahn.  Corticosteroid-induced osteopenia. , 1978, Archives of internal medicine.

[30]  L. Ibels,et al.  ASEPTIC NECROSIS OF BONE FOLLOWING RENAL TRANSPLANTATION: EXPERIENCE IN 194 TRANSPLANT RECIPIENTS AND REVIEW OF THE LITERATURE , 1978, Medicine.

[31]  W. Naudé,et al.  S.S.P.E. AND SALK VACCINE , 1973 .

[32]  R. Pugh,et al.  Transection of the oesophagus for bleeding oesophageal varices , 1973, The British journal of surgery.

[33]  J M Vogel,et al.  The effect of supplemental oral phosphate on the bone mineral changes during prolonged bed rest. , 1971, The Journal of clinical investigation.

[34]  R. Salama.  MYELOMATOUS OSTEOSCLEROSIS AND PERIPHERAL NEUROPATHY. , 1965, Lancet.

[35]  R. Eckstein,et al.  Hepatic osteodystrophy: Static and dynamic bone histomorphometry and serum bone Gla-protein in 80 patients with chronic liver disease , 1989 .

[36]  N. Vakil,et al.  Steroid-related osteonecrosis in inflammatory bowel disease. , 1989, Gastroenterology.

[37]  K. V. Rao,et al.  Long-term results and complications in renal transplant recipients. Observations in the second decade. , 1988, Transplantation.

[38]  C. Gips,et al.  Bone disease after orthotopic liver transplantation. , 1988, Journal of hepatology.

[39]  J. Compston,et al.  Low bone turnover state in primary biliary cirrhosis , 1987, Hepatology.

[40]  J. Compston,et al.  Lack of osteomalacia in chronic cholestatic liver disease. , 1986, Bone.

[41]  J. Zerwekh,et al.  Bone Disease in Primary Biliary Cirrhosis: Increased Bone Resorption and Turnover in the Absence of Osteoporosis or Osteomalacia , 1984, Hepatology.

[42]  R. Evans,et al.  QUANTITATIVE BONE HISTOLOGY: A NEW METHOD , 1980, Pathology.

[43]  F. Quaade,et al.  Fatty fools and obesity. , 1960 .